UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

European stock pickers are exploring established sectors such as ... and interpretable models. In the realm of diagnostics, Roche has expanded its digital pathology capabilities by integrating over 20 ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual ...

Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...

It operates through the following segments: Diagnostics and Pharmaceuticals ... Read More on RHHVF: Roche NewsMORE Related Stocks Indices Commodities ...

Diagnostics may not be as profitable as Pharmaceuticals ... Concluding Thoughts: Is Roche Stock A “Best Buy” Within Big Pharma In 2025? As a Roche shareholder myself, am I looking forward ...

With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient access to personalised treatment. Basel, 31 January ...

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics ...

The Diagnostics division’s sales rose 4% year ... However, pipeline setbacks weigh on the stock. Roche also expects loss of exclusivity for key drugs to impact adversely sales to the tune ...